Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Baccarani, S Pileri, JL Steegmann… - Annals of …, 2012 - annalsofoncology.org
The incidence of chronic myeloid leukemia (CML) ranges between 10 and 15
cases/106/year (age adjusted) without any major geographic or ethnic differences [1]. The …
cases/106/year (age adjusted) without any major geographic or ethnic differences [1]. The …
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
G Rosti, F Castagnetti, G Gugliotta… - Nature reviews clinical …, 2017 - nature.com
The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …
[HTML][HTML] Chronic myeloid leukemia in 2020
R Hehlmann - Hemasphere, 2020 - journals.lww.com
New insights have emerged from maturing long-term academic and commercial clinical
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …
trials regarding optimum management of chronic myeloid leukemia (CML). Velocity of …
Chronic myeloid leukemia: a historical perspective
JM Goldman - Seminars in hematology, 2010 - Elsevier
Patients with splenomegaly and abnormally high leukocyte counts were first recognized in
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …
France, Germany, and Scotland in the 1840s. The only well-documented therapy in the 19th …
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY
SL Goldberg, JE Cortes… - American journal of …, 2017 - Wiley Online Library
Achieving successful outcomes in chronic phase‐chronic myeloid leukemia (CP‐CML)
requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY …
requires careful monitoring of cytogenetic/molecular responses (CyR/MR). SIMPLICITY …
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
G Gugliotta, F Castagnetti, F Palandri… - Blood, The Journal …, 2011 - ashpublications.org
The median age of chronic myeloid leukemia (CML) patients is∼ 60 years, and age is still
considered an important prognostic factor, included in Sokal and EURO risk scores …
considered an important prognostic factor, included in Sokal and EURO risk scores …
Chronic myelogenous leukemia, version 1.2015
Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated
chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) …
chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) …
The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR:: ABL1 tyrosine kinase inhibitors
The BCR:: ABL1 tyrosine kinase inhibitors (TKIs) have improved the outcomes of patients
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …
with chronic myeloid leukemia (CML). After failing second‐generation TKI (2G‐TKI), the …
Comparative effectiveness of newer tyrosine kinase inhibitors versus imatinib in the first-line treatment of chronic-phase chronic myeloid leukemia across risk groups …
S Yun, ND Vincelette, JM Segar, Y Dong… - … Myeloma and Leukemia, 2016 - Elsevier
Background BCR-ABL1 tyrosine kinase inhibitors (TKIs) have significantly improved the
survival outcomes for patients with chronic myeloid leukemia (CML). In addition to imatinib, 3 …
survival outcomes for patients with chronic myeloid leukemia (CML). In addition to imatinib, 3 …
Blast and accelerated phase CML: room for improvement
J How, V Venkataraman, GS Hobbs - Hematology, 2021 - ashpublications.org
Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia
(CML). With TKI therapy, the percentage of patients who progress to accelerated phase (AP) …
(CML). With TKI therapy, the percentage of patients who progress to accelerated phase (AP) …